Shattuck Labs Inc
NASDAQ:STTK

Watchlist Manager
Shattuck Labs Inc Logo
Shattuck Labs Inc
NASDAQ:STTK
Watchlist
Price: 1.005 USD -0.5% Market Closed
Market Cap: 48m USD
Have any thoughts about
Shattuck Labs Inc?
Write Note

Shattuck Labs Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shattuck Labs Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Shattuck Labs Inc
NASDAQ:STTK
Net Issuance of Common Stock
$48.7m
CAGR 3-Years
-48%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.1B
CAGR 3-Years
-10%
CAGR 5-Years
16%
CAGR 10-Years
-15%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$782m
CAGR 3-Years
11%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$243.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shattuck Labs Inc
Glance View

Market Cap
48m USD
Industry
Biotechnology

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of dual-sided fusion proteins. The firm has created an approach to immune modulation by designing biologics with structural characteristics. Compounds derived from its Agonist Redirected Checkpoint (ARC) platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the cluster of differentiation 47/signal regulatory protein alpha (CD47/SIRPa) checkpoint interaction to restore an anti-tumor immune response and to activate the cluster of differentiation 40 (CD40) costimulatory receptor to bolster an immune response. The firm's second product candidate, SL-279252, is designed to simultaneously inhibit the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction and activate the OX40 receptor.

STTK Intrinsic Value
1.148 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is Shattuck Labs Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
48.7m USD

Based on the financial report for Dec 31, 2023, Shattuck Labs Inc's Net Issuance of Common Stock amounts to 48.7m USD.

What is Shattuck Labs Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
7%

Over the last year, the Net Issuance of Common Stock growth was 28 529%. The average annual Net Issuance of Common Stock growth rates for Shattuck Labs Inc have been -48% over the past three years , 7% over the past five years .

Back to Top